{"id":"r-chop-r-da-epoch-r-hd-mtx","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Neutropenia"},{"rate":"30-60","effect":"Anemia"},{"rate":"20-50","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Nausea/vomiting"},{"rate":"20-40","effect":"Mucositis"},{"rate":"20-40","effect":"Infection"},{"rate":"5-15","effect":"Cardiotoxicity (doxorubicin-related)"},{"rate":"10-30","effect":"Infusion reactions (rituximab)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Rituximab binds to CD20 antigen on B-cell surfaces, triggering antibody-dependent cellular cytotoxicity and direct apoptosis. The chemotherapy components (cyclophosphamide, doxorubicin, vincristine, prednisone in CHOP; etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone in DA-EPOCH; high-dose methotrexate in R-HD MTX) work through DNA damage and cell cycle disruption. Together, these regimens provide synergistic anti-lymphoma activity.","oneSentence":"R-CHOP, R-DA-EPOCH, and R-HD MTX are combination chemotherapy regimens that use rituximab (an anti-CD20 monoclonal antibody) combined with various cytotoxic chemotherapy agents to target and destroy B-cell lymphomas.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:16.720Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma (various subtypes including diffuse large B-cell lymphoma)"},{"name":"Primary CNS lymphoma (R-HD MTX regimen)"}]},"trialDetails":[{"nctId":"NCT05164770","phase":"PHASE3","title":"Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2021-03-01","conditions":"High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B Cell Lymphoma","enrollment":160},{"nctId":"NCT05097443","phase":"PHASE3","title":"Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2021-04-15","conditions":"High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma","enrollment":130},{"nctId":"NCT04152577","phase":"PHASE4","title":"R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2019-06-05","conditions":"Lymphoma, B-Cell","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"R-CHOP; R-DA-EPOCH; R-HD MTX","genericName":"R-CHOP; R-DA-EPOCH; R-HD MTX","companyName":"Shandong Provincial Hospital","companyId":"shandong-provincial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-CHOP, R-DA-EPOCH, and R-HD MTX are combination chemotherapy regimens that use rituximab (an anti-CD20 monoclonal antibody) combined with various cytotoxic chemotherapy agents to target and destroy B-cell lymphomas. Used for B-cell non-Hodgkin lymphoma (various subtypes including diffuse large B-cell lymphoma), Primary CNS lymphoma (R-HD MTX regimen).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}